Cochrane · systematic review · CD004213
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants
Ohlsson, A, Shah, SS · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 40%Moderate 4 · 40%High 2 · 20%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyComparison
Population: preterm or low birth weight infants with risk of having PDA on day 3 to 4 of life
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Presence of PDA on third to fourth day of life (after 72 hours of treatment) | RR 0.39 [0.31, 0.48] | 9 studies · 1029 participants | Moderate |
Need for surgical closure of PDA (during hospital stay) | RR 0.46 [0.22, 0.96] | 7 studies · 925 participants | Moderate |
IVH grade III to IV (during hospital stay) | RR 0.67 [0.45, 1] | 7 studies · 925 participants | Moderate |
NEC (during hospital stay) | RR 0.96 [0.61, 1.5] | 9 studies · 1028 participants | Moderate |
Gastrointestinal haemorrhage (during hospital stay) | RR 2.05 [1.19, 3.51] | 5 studies · 282 participants | Low |
Oliguria (during ibuprofen treatment) | RR 1.45 [1.04, 2.02] | 4 studies · 747 participants | High |
Serum creatinine levels (mg/dL) (after treatment) Normal values for male and female newborns (17.7 to 88.4 µmol/L) (0.23 to 1.16 mg/dL) | no estimate extracted | 6 studies · 800 participants | Low |
Comparison
Population: preterm or low birth weight infants with risk of having PDA on day 3 to 4 of life
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Presence of PDA on day 3 or 4 of life (after 72 hours of treatment) | RR 0.47 [0.3, 0.74] | 4 studies · 202 participants | Low |
Gastrointestinal haemorrhage (during hospital stay) | RR 2.01 [1.17, 3.48] | 4 studies · 202 participants | Low |
Comparison
Population: preterm or low birth weight infants with risk of having PDA on day 3 to 4 of life
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Presence of PDA on third day of life (72 hours of treatment) | no estimate extracted | 5 studies · 827 participants | High |
Comparison
Population: preterm or low birth weight infants with risk of having PDA on day 3 to 4 of life
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Presence of PDA on third to fourth day of life (after 72 hours of treatment) | RR 0.39 [0.31, 0.48] | 9 studies · 1029 participants | Moderate |
Need for surgical closure of PDA (during hospital stay) | RR 0.46 [0.22, 0.96] | 7 studies · 925 participants | Moderate |
IVH grade III to IV (during hospital stay) | RR 0.67 [0.45, 1] | 7 studies · 925 participants | Moderate |
NEC (during hospital stay) | RR 0.96 [0.61, 1.5] | 9 studies · 1028 participants | Moderate |
Gastrointestinal haemorrhage (during hospital stay) | RR 2.05 [1.19, 3.51] | 5 studies · 282 participants | Low |
Oliguria (during ibuprofen treatment) | RR 1.45 [1.04, 2.02] | 4 studies · 747 participants | High |
Serum creatinine levels (mg/dL) (after treatment) Normal values for male and female newborns (17.7 to 88.4 µmol/L) (0.23 to 1.16 mg/dL) | no estimate extracted | 6 studies · 800 participants | Low |
Comparison
Population: preterm or low birth weight infants with risk of having PDA on day 3 to 4 of life
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Presence of PDA on day 3 or 4 of life (after 72 hours of treatment) | RR 0.47 [0.3, 0.74] | 4 studies · 202 participants | Low |
Gastrointestinal haemorrhage (during hospital stay) | RR 2.01 [1.17, 3.48] | 4 studies · 202 participants | Low |
Comparison
Population: preterm or low birth weight infants with risk of having PDA on day 3 to 4 of life
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Presence of PDA on third day of life (72 hours of treatment) | no estimate extracted | 5 studies · 827 participants | High |